Literature DB >> 23407222

The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.

E H Decloedt1, J Mwansa-Kambafwile, J-S van der Walt, H McIlleron, P Denti, P Smith, L Wiesner, M Rangaka, R J Wilkinson, G Maartens.   

Abstract

Isoniazid preventive therapy (IPT) is recommended in patients on antiretroviral treatment. Isoniazid (INH) inhibits CYP3A4, which metabolises nevirapine (NVP). Administration of INH may cause higher NVP concentrations and toxicity. We studied the effect of INH on NVP concentrations in 21 patients randomised to either placebo (n = 13) or INH (n = 8) in an ongoing trial of IPT in patients on ART. INH was associated with a 24% increase in median NVP area under the plasma concentration-time curve for the 12 h dosing interval, which was not statistically significant (P = 0.66).

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23407222      PMCID： PMC4176729          DOI： 10.5588/ijtld.12.0427

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  8 in total

1.  Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.

Authors:  Betty J Dong; Yu Zheng; Michael D Hughes; Adam Frymoyer; Davide Verotta; Patricia Lizak; Frederick Sawe; Judith S Currier; Shahin Lockman; Francesca T Aweeka
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

2.  6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.

Authors:  Taraz Samandari; Tefera B Agizew; Samba Nyirenda; Zegabriel Tedla; Thabisa Sibanda; Nong Shang; Barudi Mosimaneotsile; Oaitse I Motsamai; Lorna Bozeman; Margarett K Davis; Elizabeth A Talbot; Themba L Moeti; Howard J Moffat; Peter H Kilmarx; Kenneth G Castro; Charles D Wells
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

3.  Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Authors:  Z Desta; N V Soukhova; D A Flockhart
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  A simple method for determining acetylator phenotype using isoniazid.

Authors:  A Hutchings; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

5.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

Authors:  D A Erickson; G Mather; W F Trager; R H Levy; J J Keirns
Journal:  Drug Metab Dispos       Date:  1999-12       Impact factor: 3.922

6.  Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.

Authors:  Zegabriel Tedla; Samba Nyirenda; Crandall Peeler; Tefera Agizew; Thabisa Sibanda; Oaitse Motsamai; Andrew Vernon; Charles D Wells; Taraz Samandari
Journal:  Am J Respir Crit Care Med       Date:  2010-04-08       Impact factor: 21.405

7.  Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.

Authors:  C A Peloquin; G S Jaresko; C L Yong; A C Keung; A E Bulpitt; R W Jelliffe
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

8.  Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.

Authors:  Karen Cohen; Gilles van Cutsem; Andrew Boulle; Helen McIlleron; Eric Goemaere; Peter J Smith; Gary Maartens
Journal:  J Antimicrob Chemother       Date:  2007-12-19       Impact factor: 5.790
  8 in total
  4 in total

1.  Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old.

Authors:  Anthony Enimil; Sampson Antwi; Hongmei Yang; Albert Dompreh; Wael A Alghamdi; Fizza S Gillani; Antoinette Orstin; Dennis Bosomtwe; Theresa Opoku; Jennifer Norman; Lubbe Wiesner; Taimour Langaee; Charles A Peloquin; Michael H Court; David J Greenblatt; Awewura Kwara
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

2.  Pharmacokinetics of isoniazid in low-birth-weight and premature infants.

Authors:  A Bekker; H S Schaaf; H I Seifart; H R Draper; C J Werely; M F Cotton; A C Hesseling
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

3.  Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.

Authors:  David W Haas; Anthony T Podany; Yajing Bao; Susan Swindells; Richard E Chaisson; Noluthando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Constance A Benson; Paxton Baker; Courtney V Fletcher
Journal:  Pharmacogenet Genomics       Date:  2021-01       Impact factor: 2.000

4.  A Comparison of Adverse Drug Reaction Profiles in Patients on Antiretroviral and Antitubercular Treatment in Zimbabwe.

Authors:  Josiah T Masuka; Precious Chipangura; Priscilla P Nyambayo; Andy Stergachis; Star Khoza
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 3.580
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.